<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Quinupristin and dalfopristin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Quinupristin and dalfopristin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Quinupristin and dalfopristin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11419" href="/d/html/11419.html" rel="external">see "Quinupristin and dalfopristin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12758" href="/d/html/12758.html" rel="external">see "Quinupristin and dalfopristin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F216636"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Synercid [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F216659"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Streptogramin</li></ul></div>
<div class="block doa drugH1Div" id="F216639"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Use of quinupristin/dalfopristin is limited by poor tolerance and frequent need for administration via central line (Kullar 2016; O’Driscoll 2015; Reissier 2021).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients who cannot receive other agents due to intolerance or resistance (IDSA [Mermel 2009]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for ampicillin- and vancomycin-resistant E. faecium: </i>
<b>IV:</b> 7.5 mg/kg every 8 hours; maximum dose is not established. Treat uncomplicated bacteremia for 7 to 14 days from day of first negative blood culture (IDSA [Mermel 2009]). Some experts recommend a duration of 5 to 7 days for uncomplicated infection with rapid blood culture clearance (within 24 hours) and in the absence of metastatic infection (Murray 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e7e2352-c000-447d-a037-fc6a2f2622e8">CNS infection, health care–associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS infection, health care–associated (eg, cerebrospinal fluid shunt infection) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients who cannot receive other agents due to intolerance or resistance (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for ampicillin- and vancomycin-resistant E. faecium:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i></i></b>
<b>IV: </b>7.5 mg/kg every 8 hours for ≥10 days; maximum dose is not established (IDSA [Tunkel 2017]; Knoll 2013; Tush 1998; Williamson 2002).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intraventricular (adjunct to systemic therapy; use a preservative-free preparation) (off-label):</b>
<b>Note: </b>Reserve use for when parenteral therapy fails or for cerebrospinal fluid (CSF) shunt infections when the shunt cannot be removed (Baddour 2021).</p>
<p style="text-indent:-2em;margin-left:8em;">2 to 5 mg daily (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]; Tan 2000). When administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in CSF). Duration is individualized according to clinical and microbiologic response (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8393ad2f-5f04-4843-b3ac-9564d4127696">Skin and soft tissue infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, complicated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients who cannot receive other agents due to intolerance or resistance (IDSA [Stevens 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 7.5 mg/kg every 12 hours for at least 7 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990360"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Renal impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer’s labeling; however, the high molecular weights of quinupristin and dalfopristin suggest that they are unlikely to be removed by hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987735"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, pharmacokinetic data suggest dosage adjustment may be necessary.</p></div>
<div class="block doe drugH1Div" id="F216640"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F216652"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12758" href="/d/html/12758.html" rel="external">see "Quinupristin and dalfopristin: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">Dosage is expressed in terms of combined “mg” of quinupristin plus dalfopristin:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b> Severe infection: Infants, Children, and Adolescents: Limited data available in infants and children &lt;12 years: IV: 7.5 mg/kg every 8 to 12 hours (Liu 2011; Loeffler 2002; <i>Red Book</i> [AAP 2018])</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2345e8ab-b7d9-4b2f-b0bc-0f76f1d75643">Enterococcus faecium, vancomycin resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Enterococcus faecium</i>, vancomycin resistant (VREF):</b> Limited data available: Infants, Children, and Adolescents: IV: 7.5 mg/kg/dose every 8 hours; dosing based on an Emergency-Use Program (n=127, mean age: 7.3 years [range: 1.2 months to 17 years]) (Loeffler 2002) and two case series (total n=17, range: 10 months to 18 years) (Gray 2000; Verma 2001)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ea76474-d269-40b1-a28b-cbeda941f41a">MRSA infection, vancomycin failure salvage therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>MRSA infection, vancomycin failure salvage therapy:</b> Limited data available: Infants, Children, and Adolescents: IV: 7.5 mg/kg/dose every 8 hours (Liu 2011; Loeffler 2002)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7a61f52c-f6c4-4ef2-aadd-bd2ab2a64f6b">Skin and skin structure infection, complicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection, complicated, treatment:</b> Infants, Children, and Adolescents: Limited data available in infants and children &lt;12 years: IV: 7.5 mg/kg/dose every 12 hours for at least 7 days (<i>Red Book</i> [AAP 2018])</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e6d0e58-5114-4794-ad55-e5f004a35eda">VP-shunt infection, ventriculitis; multidrug resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>VP-shunt infection, ventriculitis; multidrug resistant:</b> Limited data available: Infants, Children, and Adolescents: Intraventricular/intrathecal <b>(use a preservative-free preparation)</b>: Usual dose: 1 to 2 mg/<b>day</b>; reported range: 1 to 5 mg; in adults, the usual range is 2 to 5 mg/day; use in combination with IV quinupristin/dalfopristin therapy (IDSA [Tunkel 2017]; Nachman 1995; Tush 1998)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159774"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is required for use in patients with renal impairment or patients undergoing peritoneal dialysis. Not removed by peritoneal dialysis or hemodialysis</p></div>
<div class="block dohp drugH1Div" id="F51159775"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer labeling; not studied; pharmacokinetic data suggest adjustment may be necessary.</p></div>
<div class="block adr drugH1Div" id="F216611"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site pain (40% to 45%), infusion-site reaction (12% to 13%), local inflammation (infusion site: 38% to 42%), localized edema (infusion site: 17% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombophlebitis (≤2%), thrombosis (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (1%), increased lactate dehydrogenase (3%), increased serum glucose (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3%), nausea (4% to 5%), vomiting (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (2%), increased serum bilirubin (&lt;1%; increased direct serum bilirubin: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (2%), pain (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, palpitations, peripheral edema, phlebitis, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, maculopapular rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum bicarbonate, hyperkalemia, hypoglycemia, hyponatremia, increased serum bicarbonate</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, <i>Clostridioides difficile</i> colitis, constipation, dyspepsia, oral candidiasis, pancreatitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria, vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased hematocrit, thrombocythemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, confusion, dizziness, hypertonia, insomnia, myasthenia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, gout, lower limb cramp, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, low blood pCO2, pleural effusion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Sweet syndrome (Choi 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, angioedema</p></div>
<div class="block coi drugH1Div" id="F216623"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to quinupristin, dalfopristin, other streptogramins (eg, pristinamycin, virginiamycin), or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F216608"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arthralgias/myalgias: May cause arthralgias and/or myalgias, sometimes severe; reversible with treatment discontinuation. Reduction of dosing frequency has led to improvement in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperbilirubinemia: May cause hyperbilirubinemia (&gt;5 times ULN; primarily conjugated bilirubin) possibly through competition for excretory pathways.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phlebitis: May cause pain and phlebitis when infused through a peripheral line (not relieved by hydrocortisone or diphenhydramine).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p></div>
<div class="block foc drugH1Div" id="F216618"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Synercid: 500 mg: Quinupristin 150 mg and dalfopristin 350 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F216604"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323773"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Synercid Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-350 mg (per each): $559.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F216620"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Line should be flushed with D5W prior to and following administration. Infusion should be completed over 60 minutes (toxicity may be increased with shorter infusion). If severe venous irritation occurs following peripheral administration, quinupristin/dalfopristin may be further diluted (to 500 mL or 750 mL), infusion site changed, or infused by a peripherally inserted central catheter or a central venous catheter. In general, administration by central venous catheter is required to avoid phlebitis (Kullar 2016; O'Driscoll 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal/Intraventricular (off-label route):</b> Use preservative-free preparations only. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow quinupristin-dalfopristin solution to equilibrate in the CSF (IDSA [Tunkel 2017]).</p></div>
<div class="block admp drugH1Div" id="F52613788"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer IV infusion over 60 minutes (toxicity may be increased with shorter infusion); prior to and following administration, the infusion line should be flushed with D5W to minimize venous irritation; <b>DO NOT FLUSH</b> with saline or heparin solutions due to incompatibility. If severe venous irritation occurs following peripheral administration, quinupristin/dalfopristin may be further diluted, infusion site changed, or infused by a peripherally inserted central catheter (PICC) or a central venous catheter.</p></div>
<div class="block use drugH1Div" id="F216619"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Skin and soft tissue infections, complicated:</b> Treatment of complicated skin and skin structure infections caused by methicillin-susceptible <i>Staphylococcus aureus</i> or <i>Streptococcus pyogenes.</i>
<b>Note: </b>Use of quinupristin/dalfopristin is limited by poor tolerance and frequent need for administration via central line (Kullar 2016; O’Driscoll 2015; Reissier 2021).</p></div>
<div class="block off-label drugH1Div" id="F25731760"><span class="drugH1">Use: Off-Label: Adult</span><p>Bloodstream infection; CNS infection, health care–associated (eg, cerebrospinal fluid shunt infection)</p></div>
<div class="block mst drugH1Div" id="F56413004"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F216654"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F216613"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: Quinupristin and Dalfopristin may increase the serum concentration of Cisapride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Quinupristin and Dalfopristin may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F216625"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F6055734"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if quinupristin/dalfopristin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering quinupristin/dalfopristin to a nursing woman. The increased molecular weight of quinupristin/dalfopristin may minimize excretion into human milk. Nondose-related effects could include modification of bowel flora.</p></div>
<div class="block mop drugH1Div" id="F13493234"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Culture and sensitivity, conjugated bilirubin if clinically indicated</p></div>
<div class="block pha drugH1Div" id="F216607"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Quinupristin/dalfopristin inhibits bacterial protein synthesis by binding to different sites on the 50S bacterial ribosomal subunit thereby inhibiting protein synthesis</p></div>
<div class="block phk drugH1Div" id="F216622"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Quinupristin: 0.45 L/kg; Dalfopristin: 0.24 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Quinupristin is conjugated with glutathione and cysteine to active metabolites; dalfopristin is hydrolyzed to an active metabolite </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Quinupristin: 0.85 hour; Dalfopristin: 0.7 hour (mean elimination half-lives, including metabolites: 3 and 1 hours, respectively) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (75% to 77% as unchanged drug and metabolites); urine (15% to 19%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038795"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Synercid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference">
                  Baddour L, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8875130">
<a name="8875130"></a>Bryson HM, Spencer CM. Quinupristin/Dalfopristin. <i>Drugs</i>. 1996;52(3):406-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/8875130/pubmed" id="8875130" target="_blank">8875130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8845540">
<a name="8845540"></a>Chant C, Rybak MH. Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic. <i>Ann Pharmacother</i>. 1995;29(10):1022-1027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/8845540/pubmed" id="8845540" target="_blank">8845540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16872491">
<a name="16872491"></a>Chesi G, Colli A, Mestres CA, Gambarati G, Boni F, Gherli T. Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. <i>BMC Infect Dis</i>. 2006;6:124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/16872491/pubmed" id="16872491" target="_blank">16872491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14619389">
<a name="14619389"></a>Choi HS, Kim HJ, Lee TH, et al. Quinupristin/dalfopristin-induced Sweet's syndrome. <i>Korean J Intern Med</i>. 2003;18(3):187-190. doi:10.3904/kjim.2003.18.3.187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/14619389/pubmed" id="14619389" target="_blank">14619389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11062197">
<a name="11062197"></a>Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. <i>J Antimicrob Chemother</i>. 2000;46(5):775-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11062197/pubmed" id="11062197" target="_blank">11062197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10991879">
<a name="10991879"></a>Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. <i>Antimicrob Agents Chemother</i>. 2000;44(10):2880-2882.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/10991879/pubmed" id="10991879" target="_blank">10991879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11401187">
<a name="11401187"></a>Garey KW, Tesoro E, Muggia V, et al. Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. <i>Pharmacotherapy</i>. 2001;21(6):748-750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11401187/pubmed" id="11401187" target="_blank">11401187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9713046">
<a name="9713046"></a>Gransden WR, King A, Marossy D, et al. Quinupristin/Dalfopristin in Neonatal <i>Enterococcus faecium</i> Meningitis. <i>Arch Dis Child Fetal Neonatal Ed</i>. 1998;78(3):F235-F236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/9713046/pubmed" id="9713046" target="_blank">9713046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10749466">
<a name="10749466"></a>Gray JW, Darbyshire PJ, Beath SV, et al. Experience With Quinupristin/Dalfopristin in Treating Infections With Vancomycin-Resistant <i>Enterococcus faecium</i> in Children. <i>Pediatr Infect Dis J</i>. 2000;19(3):234-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/10749466/pubmed" id="10749466" target="_blank">10749466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8870891">
<a name="8870891"></a>Griswold MW, Lomaestro BM, Briceland LL. Quinupristin-Dalfopristin (RP 59500): An Injectable Streptogramin Combination. <i>Am J Health Syst Pharm</i>. 1996;53:2045-2053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/8870891/pubmed" id="8870891" target="_blank">8870891</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gupte G, Jyothi S, Graham S, et al. Synercid Use in Children Is Associated With Arthralgia and Myalgia. <i>Archives of Disease in Childhood</i>. 2006;91(supp 1):67.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320109">
<a name="26320109"></a>Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <i>Eur Heart J</i>. 2015;36(44):3075-3128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26320109/pubmed" id="26320109" target="_blank">26320109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22992165">
<a name="22992165"></a>Knoll BM, Hellmann M, Kotton CN. Vancomycin-resistant Enterococcus faecium meningitis in adults: case series and review of the literature. <i>Scand J Infect Dis</i>. 2013;45(2):131-139. doi:10.3109/00365548.2012.717711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/22992165/pubmed" id="22992165" target="_blank">22992165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26565015">
<a name="26565015"></a>Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. <i>J Antimicrob Chemother</i>. 2016;71(3):576-586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26565015/pubmed" id="26565015" target="_blank">26565015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary. <i>Clin Infect Dis</i>. 2011;52(3):285-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12394819">
<a name="12394819"></a>Loeffler AM, Drew RH, Perfect JR, et al. Safety and Efficacy of Quinupristin/Dalfopristin for Treatment of Invasive Gram-Positive Infections in Pediatric Patients. <i>Pediatr Infect Dis J</i>. 2002;21(10):950-956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/12394819/pubmed" id="12394819" target="_blank">12394819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9868693">
<a name="9868693"></a>Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. <i>Clin Infect Dis</i>. 1998;27(6):1554-1556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/9868693/pubmed" id="9868693" target="_blank">9868693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10543762">
<a name="10543762"></a>Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. <i>Antimicrob Agents Chemother</i>. 1999;43(11)2776-2779.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/10543762/pubmed" id="10543762" target="_blank">10543762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Murray BE. Treatment of enterococcal infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9156389">
<a name="9156389"></a>Nachman SA, Verma R, Egnor M. Vancomycin-Resistant <i>Enterococcus faecium</i> Shunt Infection in an Infant: An Antibiotic Cure. <i>Microb Drug Resist</i>. 1995;1(1):95-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/9156389/pubmed" id="9156389" target="_blank">9156389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26244026">
<a name="26244026"></a>O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. <i>Infect Drug Resist</i>. 2015;8:217-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/26244026/pubmed" id="26244026" target="_blank">26244026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11181142">
<a name="11181142"></a>Olsen KM, Rebuck JA, Rupp ME. Arthralgias and Myalgias Related to Quinupristin-Dalfopristin Administration. <i>Clin Infect Dis</i>. 2001;32(4):e83-e86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11181142/pubmed" id="11181142" target="_blank">11181142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33030387">
<a name="33030387"></a>Reissier S, Cattoir V. Streptogramins for the treatment of infections caused by Gram-positive pathogens. <i>Expert Rev Anti Infect Ther</i>. 2021;19(5):587-599. doi:10.1080/14787210.2021.1834851<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/33030387/pubmed" id="33030387" target="_blank">33030387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Synercid (quinupristin dalfopristin) [prescribing information]. New York, NY: Pfizer Injectables; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11041712">
<a name="11041712"></a>Tan TY, Pitman I, Penrose-Stevens A, et al. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. <i>J Infect</i>. 2000;41(1):95-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11041712/pubmed" id="11041712" target="_blank">11041712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14515928">
<a name="14515928"></a>Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. <i>South Med J</i>. 2003;96(8):818-820.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/14515928/pubmed" id="14515928" target="_blank">14515928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9636880">
<a name="9636880"></a>Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. <i>Clin Infect Dis</i>. 1998;26(6):1460-1461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/9636880/pubmed" id="9636880" target="_blank">9636880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11152440">
<a name="11152440"></a>Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. <i>J Antimicrob Chemother</i>. 2001;47(1):105-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11152440/pubmed" id="11152440" target="_blank">11152440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11792478">
<a name="11792478"></a>Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. <i>Clin Neurol Neurosurg</i>. 2002;104(1):54-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinupristin-and-dalfopristin-drug-information/abstract-text/11792478/pubmed" id="11792478" target="_blank">11792478</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9515 Version 167.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
